Posted On: 02/24/2016 3:59:20 PM
Post# of 30066
IF gerald doesn't drag out ESS and postponing things like most of the times then i expect to have results in from clinical trails this year.
Good thing is is that ESS heals up pretty quick! 30 days for wound closure i believe?
once we have good results in (which is a matter of time imo) then we should be good to sell it i would think.
From my experience sometimes products get bought after good phase 2 data by big pharma. And listening to Gerald (he could be hyping again!) saying there is lots of interest in ESS, it should be no problem to sell it imo.
We have so much going for us with so much potential but the only worry i have is that gerald manages to postpone progress for some reason and that ESS trials will still not be started in 2016! (i'm a bit over exaggerating now but you get the point).
Good thing is is that ESS heals up pretty quick! 30 days for wound closure i believe?
once we have good results in (which is a matter of time imo) then we should be good to sell it i would think.
From my experience sometimes products get bought after good phase 2 data by big pharma. And listening to Gerald (he could be hyping again!) saying there is lots of interest in ESS, it should be no problem to sell it imo.
We have so much going for us with so much potential but the only worry i have is that gerald manages to postpone progress for some reason and that ESS trials will still not be started in 2016! (i'm a bit over exaggerating now but you get the point).
(2)
(0)
